Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with ...

Fintel reports that on December 18, 2025, Truist Securities maintained coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 31.68% Upside As of December 5, ...

Fintel reports that on November 19, 2025, UBS upgraded their outlook for Insulet (NasdaqGS:PODD) from Neutral to Buy. Analyst Price Forecast Suggests 9.42% Upside As of November 17, 2025, the average ...

Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock also fell short of the S&P 500’s 11.9% gain during that period. Is now the ...

Investors might want to bet on Insulet (PODD), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing. NanoViricides’ Current ...

Microsoft will soon sunset WSA but there are other ways to run Android apps on Windows. The two ways to run Android apps are using the Google Play Games emulator and Phone Link to stream Android apps.

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the ...

Insulet Corporation PODD reported third-quarter 2024 adjusted earnings per share (EPS) of 90 cents, up significantly 26.8% from the year-ago period’s figure. The bottom line surpassed the Zacks ...